We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FINE-ONE trial assessed finerenone use by adults ...

Compared with monotherapy, finerenone plus empagliflozin was associated with improved kidney outcomes in T2D and CKD regardless of GLP-1RA use. Compared with monotherapy and regardless of prior ...

HOUSTON — The nonsteroidal mineralocorticoid-receptor antagonist drug finerenone led to significant reductions in albuminuria in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) ...

1. Among patients with both chronic kidney disease (CKD) and type 2 diabetes (T2D) already on a renin-angiotensin system (RAS) inhibitor, a combination of finerenone and empagliflozin resulted in a ...

A new analysis suggests that finerenone (Kerendia), a newer heart failure medication, may help older adults rely less on high doses of water pills. The findings come from the large FINEARTS-HF ...

Finerenone reduced heart failure events and cardiovascular deaths in patients with HFmrEF or HFpEF when used with diuretics. The study found finerenone reduced hypokalemia risk but increased ...

Early combination therapy could translate into fewer downstream hospitalizations and lower costs associated with dialysis and cardiovascular complications. Combination therapy of finerenone and ...